At GUNA we are well aware that the ultimate goal of any company is to do business, and we recognize ourselves in this model without any false pretences, but we are also convinced that profit-seeking cannot and must not be separated from objectives of an ethical and social nature, and that business can have a human face.
As a business, we perceive that we have various kinds of responsibilities: we must invest in scientific research, in occupation, in technological innovation, in the well-being of our employees and of the territory in which we live, in improving the general health of the nations in which we operate, and in furthering a better-educated and more sensitive approach to the concepts of health and disease.
GUNA wants to look to the future, committing itself to guaranteeing its contribution to the well-being of the community, without using its resources to “protect the past”.
With this letter, the company consequently wishes to make it known that it has eliminated all the patent protection procedures for the industrial products and processes regarding the whole range of preparations that it manufactures.
GUNA has recently invested considerable resources in building and commissioning its new laboratories in via Palmanova, Milan; from the technological standpoint, these are the most advanced industrial production units in the low dose sector in the world. The company is also implementing a five-year plan entailing further significant investments in scientific research. Every innovation in its technologies, products and processes resulting from its activities at the new laboratories, and at every other local research unit run by the company in Italy and abroad, will be made available to the market unprotected by any patents, and every new publication, be it scientific or for the general public’s information, that is edited by the company (which includes the results of the clinical studies financed by GUNA) will also be “copyleft” (i.e. it can be freely circulated without any need for prior authorization, providing the source is quoted).
We see the use of patents as a heavy burden that interferes with the natural dynamic drive behind the development of new understanding. In this third millennium we are faced with ambitious new challenges that can hopefully be met providing we base our activity on different values – focusing primarily on sharing our know-how at all levels.
In our own small way, we are strongly determined to make a genuine contribution. GUNA can hardly hope to have all patents and copyrights abolished or outlawed, but we do have the ambition of making our own, carefully pondered and rational decisions and, with this letter, we invite all those protagonists of the pharmaceutical sector that are striving for quality and efficiency to reflect on the benefits derivable for all concerned – businesses and patients – from focusing our resources and energies on a freely-circulating and shared scientific research instead of on obsessively protecting our own know-how.
In a nutshell, we hope that in future there will be a more “holistic” approach to the management of knowledge, just as low dose medicine proposes a holistic approach to the patient’s health.
GUNA Spa President
Dr. Alessandro Pizzoccaro